Antiarrhythmic Therapy

Principles of Pediatric Antiarrhythmic Therapy

• The majority of antiarrhythmic agents are not approved by the U.S. Food and Drug Administration (FDA) for use in children, making their prescription largely "off-label" and reliant on pediatric cardiology expertise and well-recognized dosing standards.
• The selection of an appropriate antiarrhythmic agent requires balancing the mechanism of the arrhythmia against the potential for intolerable drug side effects and the risk of proarrhythmia (the induction of a new, dangerous arrhythmia by the drug itself).
• Prior to initiating antiarrhythmic therapy, reversible causes of arrhythmias must be identified and corrected, including electrolyte derangements (such as hypokalemia, hypocalcemia, or hypomagnesemia), hypoxia, metabolic acidosis, and drug toxicity.
• Antiarrhythmic medications are classically categorized using the Vaughan-Williams classification system, which divides drugs into four primary classes based on their dominant electrophysiological mechanism of action, alongside a fifth miscellaneous class.

Diagnostic Investigations

Auscultation

• Auscultation is crucial for identifying the hemodynamic impact of arrhythmias and monitoring for drug-induced complications.
• A new pathologic gallop rhythm or signs of pulmonary congestion (crackles) may indicate the development of tachycardia-induced cardiomyopathy from an incessant arrhythmia or reflect a severe negative inotropic effect from agents like flecainide, propafenone, or verapamil.
• The relationship between the heart rate and respiratory phases can be appreciated on careful auscultation to diagnose normal phasic sinus arrhythmia, which is exaggerated by vagotonic drugs like digoxin.

Electrocardiogram (ECG)

• Baseline and serial ECG monitoring is mandatory during the initiation and maintenance of antiarrhythmic therapy to assess for efficacy and drug-induced conduction delays.
• Class IA and IC agents (e.g., procainamide, flecainide) slow depolarization, requiring close monitoring for QRS complex widening; procainamide infusions must be halted if the QRS complex widens by greater than 50%.
• Class III agents (e.g., amiodarone, sotalol) prolong repolarization, necessitating serial measurements of the QTc interval to prevent extreme prolongation and the subsequent risk of Torsades de Pointes.
• Digoxin toxicity manifests on the ECG with PR-interval prolongation, high-grade atrioventricular (AV) block, and hyperkalemia.
• Intravenous adenosine provides diagnostic utility on the ECG; by creating transient AV block, it terminates AV node-dependent tachycardias abruptly with a P wave, or it unmasks the underlying "saw-tooth" flutter waves in atrial flutter.

Echocardiography

• A comprehensive transthoracic echocardiogram must be performed prior to the initiation of specific antiarrhythmic therapies to rule out underlying structural congenital heart disease and assess biventricular systolic function.
• The presence of moderate to severe ventricular dysfunction or coronary artery disease is an absolute contraindication for the use of Class IC agents (flecainide, propafenone) due to their profound negative inotropic and proarrhythmic effects.

Cardiac Catheterization

• Invasive electrophysiology study (EPS) in the cardiac catheterization laboratory is utilized when medical therapy is ineffective, poorly tolerated, or when precise mapping of an arrhythmic substrate (like an accessory pathway) is required for transcatheter ablation.
• EPS evaluates the conduction characteristics of the AV node and accessory pathways, and can be used to assess the efficacy of antiarrhythmic drugs in preventing the inducibility of the tachycardia.

Vaughan-Williams Classification and Specific Agents

Class I: Sodium Channel Blockers

• Class I agents exert their effects by inhibiting the fast sodium channels, thereby decreasing the speed of depolarization and slowing conduction velocity.

Class II: Beta-Adrenergic Blockers

• Beta-blockers reduce heart rate, myocardial contractility, and myocardial oxygen demand by competitively antagonizing circulating catecholamines.

Class III: Potassium Channel Blockers

• Class III agents predominantly block potassium channels, thereby prolonging the action potential duration and the effective refractory period.

Class IV: Calcium Channel Blockers and Miscellaneous Agents

• Calcium channel blockers inhibit the inward calcium current, predominantly slowing conduction through the AV node and depressing sinus node automaticity.